

**Please amend the specification as follows:**

At page 38-39 of the substitute specification entered in Applicant's February 14, 2003 response to the first Official Action, please enter amended paragraph [0115] as shown below.

(Currently amended) [0115] A murine monoclonal antibody is obtained by immunizing mice with the recombinant human RIIB protein and spleen cells fused to obtain hybridomas, as described above. The resulting hybridomas are screened [[screening]] for [[selective]] diminished binding to RIIB, while not altering binding to RIIA or RIIIA or RIIIB. Antibodies with the desired properties are then cloned and the mRNA isolated and converted into cDNA for the heavy and light chains. A single chain Fv is then constructed as described above and expressed as a gene III fusion protein for phage display or Aga2p fusion for yeast display. A randomly mutagenized library is constructed for the single chain Fv binding and screening by panning for specificity in diminished affinity for RIIB over RIIA. The resulting phage or yeast cells are characterized by isolating the fusion phage genome or plasmid, respectively, DNA sequenced and then expressed as a recombinant antibody.